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Abstract
Background: Tuberous sclerosis complex (TSC), a tumor syndrome caused by mutations in TSC1 or TSC2 genes, is
characterized by the development of hamartomas. We previously isolated, from an angiomyolipoma of a TSC2 patient, a
homogenous population of smooth muscle-like cells (TSC22/2 ASM cells) that have a mutation in the TSC2 gene as well as
TSC2 loss of heterozygosity (LOH) and consequently, do not produce the TSC2 gene product, tuberin. TSC22/2 ASM cell
proliferation is EGF-dependent.
Methods and Findings: Effects of EGF on proliferation of TSC22/2 ASM cells and TSC22/2 ASM cells transfected with TSC2
gene were determined. In contrast to TSC22/2 ASM cells, growth of TSC2-transfected cells was not dependent on EGF.
Moreover, phosphorylation of Akt, PTEN, Erk and S6 was significantly decreased. EGF is a proliferative factor of TSC22/2 ASM
cells. Exposure of TSC22/2 ASM cells to anti-EGFR antibodies significantly inhibited their proliferation, reverted reactivity to
HMB45 antibody, a marker of TSC22/2 cell phenotype, and inhibited constitutive phosphorylation of S6 and ERK. Exposure of
TSC22/2 ASM cells to rapamycin reduced the proliferation rate, but only when added at plating time. Although rapamycin
efficiently inhibited S6 phosphorylation, it was less efficient than anti-EGFR antibody in reverting HMB45 reactivity and
blocking ERK phosphorylation. In TSC22/2 ASM cells specific PI3K inhibitors (e.g. LY294002, wortmannin) and Akt1 siRNA had
little effect on S6 and ERK phosphorylation. Following TSC2-gene transfection, Akt inhibitor sensitivity was observed.
Conclusion: Our results show that an EGF independent pathway is more important than that involving IGF-I for growth and
survival of TSC2/2 ASM cells, and such EGF-dependency is the result of the lack of tuberin.
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Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant
disorder characterized by the development of hamartomas, which
are unusual tumor-like growths found in a variety of tissues [1].
The two genes implicated in tuberous sclerosis, TSC1 and TSC2,
with loci on chromosomes 9q34 (TSC1) and 16p13.3 (TSC2)
respectively [2,3], participate in the control of cell size via the
insulin/p70 ribosomal S6 kinase 1 (S6K1) pathway [4]. The TSC1
gene codes for hamartin, a 130-kDa hydrophilic protein with no
homology to tuberin, the 200-kDa protein encoded by TSC2 gene
[1]. Tuberin and hamartin function together as a heterodimer to
inhibit mammalian target of rapamycin (mTOR)-mediated
signaling to S6K [5,6]. This complex acts downstream of PI3K
and Akt, and upstream of Rheb, mTOR and p70S6K1. In
mammalian cells, Rheb overexpression greatly enhances mTOR
signaling. The lack of tuberin or hamartin promotes p70S6K
activation and S6 phosphorylation, and increased DNA synthesis
in cultures of patient [7], and established cell lines [8].
Insulin and other growth factors are thought to regulate the
phosphorylation of S6K1 and 4E-binding protein 1 (4EBP1)
through the PI3K-signaling pathway via phosphorylation and
activation of Akt [9,10]. Tuberin regulates and is, itself, regulated
by p42/44 mitogen-activated protein kinase (MAPK). Activation
of the MAPK pathway by growth factors leads to phosphorylation
of two MAPKs, Erk-1 (p44mapk) and Erk-2 (p42mapk), which
translocate to the nucleus to regulate gene transcription. The
tuberin-dependent phosphorylation of B-raf and p42/44 MAPK,
the p42/44 MAPK-dependent direct phosphorylation of tuberin
and that mediated through S6K suggest an interaction between
MAPK pathway and tuberin [11,12,13]. Ras/MAPK and PI3K
pathways converge on the tumor suppressor tuberin to inhibit its
function [12]. MAPK-dependent phosphorylation of tuberin may
lead to somatic inactivation of the hamartin/tuberin complex in
tuberous sclerosis complex-associated brain hamartomas that have
activated MEK1 and ERK1 [14].
We have isolated and characterized a homogenous population of
human smooth muscle like-cells (TSC22/2ASM cells) from an
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angiomyolipoma obtained from a TSC2 patient after total
nephrectomy. The cells bear a germline TSC2 mutation, consisting
of a single base-pair change resulting in replacement of lysine 698
with a stop codon (K698X), as well as loss of heterozygosity (LOH),
and do not express tuberin [15]. These cells present the typical
constitutive activation of S6K1 and S6, and greater phosphorylation
of Akt and ERK, contain melanocyte antigens and react with
monoclonal antibody HMB45, which recognizes the gp100 protein.
When grown in culture, these cells appear not to undergo
senescence based on morphological, biochemical, and pharmaco-
logical data. TSC22/2ASM cells require epidermal growth factor
(EGF) in the growth medium for proliferation, and its replacement
with IGF-I greatly reduces cell growth. IGF-I, however, is important
for these cells. They secrete IGF-I, which may act as a survival
factor by promoting the expression of survivin [16]. Blockade of
either EGF receptors or IGF-I receptors with specific antibodies
resulted in total cell death within 12 days [15].
In the present study, we aimed at evaluating the role of EGF
pathway in growth and survival of TSC22/2 ASM cells, and the
relationship between the lack of tuberin and the dependency on
EGF by these cells. In addition we aimed at understanding the role
of PI3K pathway. Here, we show that the EGF requirement for
human TSC22/2ASM cell growth is caused by lack of tuberin.
Blockade of the EGF receptor inhibited cell proliferation and S6
and ERK phosphorylation, and caused a rapid reversion of
phenotype, as determined by HMB45 reactivity. Rapamycin
affected cell growth only when applied at plating time. Through
the inhibition of PI3K with specific inhibitors or transient
transfection of the cells with siRNA oligomer for Akt1, we show
that proliferation of human TSC22/2ASM cell is not dependent
upon the functionality of PI3K pathway. In contrast, ERK plays a
key role in the regulation of growth. In TSC22/2 ASM cells the
PI3K inhibition, by PI3K inhibitors and siRNA Akt1, was
inefficient, while its functionality was re-stablished following
transformation with the TSC2 gene.
Materials and Methods
Cell lines
TSC22/2ASM cells were isolated, characterized and grown, as
previously described [15]. They were obtained from a renal
angiomyolipoma during total nephrectomy from a 42-year-old
female with a history of TSC2 who had given written informed
consent according to the Declaration of Helsinki. The study was
approved by the Institutional Review Board of Milan’s San Paolo
Hospital. The culture medium contained a 50/50 mixture of
DMEM/Ham F12 (Euroclone; Paignton; United Kingdom)
supplemented with hydrocortisone (261027 M) (Sigma-Aldrich,
St. Louis, USA), epidermal growth factor (10 ng/ml) (Sigma-
Aldrich), sodium selenite (561028 M) (Sigma-Aldrich), insulin
(25 mg/ml) (Sigma-Aldrich), transferrin (10 mg/ml) (Sigma-Al-
drich), ferrous sulfate (1.661026 M) (Sigma-Aldrich), and 15%
fetal bovine serum (Euroclone) as described by Arbiser et al. [17].
The CT/G human aorta vascular smooth muscle cells (VSMCs)
(ATCC, Manassas, USA) were grown with F12 medium containing
10% fetal bovine serum, 100 U/ml penicillin and streptomycin and
2 mM L-glutamine (Euroclone). GP2-293 packaging cells (BD-
Biosciences-Clontech, Palo Alto, CA USA) were grown in low-
glucose DMEM medium with 10% fetal bovine serum, 100 U/ml
each penicillin and streptomycin and 2 mM L-glutamine.
Generation of tuberin-expressing cell lines
Transfection was performed as previously described by Astrinidis
et al. (2002) [18]. Briefly, GP2-293 cells were co-transfected with
2 mg of the retroviral vector pMSCVneo (a gift from Dr. A.
Astrinidis and E.P. Henske, Fox Chase Cancer Center, Philadel-
phia, PA, USA), 1 mg pVSV-G (BD-Biosciences-Clontech) encod-
ing the viral glycoprotein, and 6 ml FuGene6 (Roche, Indianapolis,
IN, USA). Replication-deficient retroviruses were collected from the
culture after 72 h and applied to subconfluent TSC22/2ASM cells
in the presence of 8 mg/ml polybrene (Sigma-Aldrich). Cells were
transduced with empty pMSCVneo vector as a control, or a
pMSCVneo construct containing the coding region of the human
TSC2 gene. Stable clones were selected for 2 weeks in the presence
of 100 mg/ml G418 (Sigma).
Evaluation of Cell Proliferation
Cellular proliferation was evaluated by counting at least 400–
500 cells in a Neubauer chamber. TSC22/2 ASM and transfect-
ed-cells were grown with or without EGF (10 ng/ml) or
substituting IGF-1 (50 ng/ml) to EGF in the culture medium for
30 days. Cells were counted after 7, 15, 20 and 30 days. Each data
point was the mean of three independent experiments.
The actions of rapamycin (Rapamune-Sirulimus, Wyeth
Europa, UK; 1 ng/ml) and anti-EGFR (clone 225; 5 mg/ml;
Calbiochem, Darmstadt, Germany) were evaluated by adding the
drugs to TSC22/2 ASM cells at plating time or 3 hours after
plating for 12 days. The effect of different doses of rapamycin (5,
10, and 20 ng/ml) was evaluated by adding rapamycin 3 hours
after plating for 12 days. Cells were counted after 2, 5, 7, 10, 12
days. Each data point was the mean of three independent
experiments.
Immunofluorescence Microscopy
Cells were cultured on glass slides, then permeabilized with 70%
methanol for 10 min, and dried in air. The primary antibodies
against a-actin (1:100; Sigma), HMB45 (1:100; Dako, Carpinteria,
CA USA), and tuberin (C-20) (1:100; Santa Cruz, Santa Cruz,
CA, USA) were applied overnight at 4uC. The samples were
incubated for three hours at room temperature with fluorescein
isothiocyanate (FITC)-conjugated rabbit anti-mouse antibody
(Chemicon, Temecula, CA, USA) for HMB45, and a-actin and
rhodamine-conjugated goat anti-rabbit antibody (Chemicon) for
studies with tuberin. After washing, the slides were mounted in
FluorSave reagent (Calbiochem, Darmstadt, Germany).
HMB45 reactivity was evaluated by immunofluorescence.
TSC22/2 ASM cells were incubated for 48 hours or 5 days.
Rapamycin (1 ng/ml) or anti-EGFR (5 mg/ml) was added at
plating time or 3 hours after plating. HMB45 labeling was defined
as strong (++), intermediate (+) and negative (2). HMB45
reactivity was evaluated also after TSC2-transfection. Quantifica-
tion of HMB45 intensity was achieved with a confocal microscope
(Leica TCS-SP2) and analyzed by Leica Confocal software using
the profile through stack/series methods as follows: 30 equal
polygonal areas covering the cells were randomly selected for each
image. The fluorescence intensity values of the selected cells were
quantified and the mean and the standard deviation of the data
were calculated by the GraphPad software. The level of statistical
significance was determined by Student’s t-test.
Cell treatment
For evaluating the effects of anti-EGFR and rapamycin on
TSC22/2 ASM cells rapamycin (1 ng/ml) or anti-EGFR antibody
(5 mg/ml) were added to the culture medium at plating time or
3 hours after plating for 24 or 48 hours.
For PI3K pathway evaluation , TSC22/2 ASM and transfected
cells were incubated for 2 hours with IGF-I (50 ng/ml) with or
without LY294002 (20 mM), PD98059 (30 mM), or wortmannin
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(80 nm or 320 nM). The experiments were performed in complete
medium or after 24 hours starvation.
Western blotting
Cells were lysed in lysis buffer (5 mM EDTA, 100 mM
deoxycholic acid, 3% SDS). Samples (50 mg per lane) were boiled
for 5 min, and analyzed by 10% SDS-PAGE. After transfer to
nitrocellulose membranes (Amersham, Arlington Height, USA)
and blocking at room temperature for 3 h with 5% dry milk
(Merck, Darmstadt, Germany), membranes were incubated
overnight at 4uC with antibodies against tuberin (C-20) (1:100;
Santa Cruz), phospho-Akt (1:1000; Cell Signaling; Beverly, CA,
USA), Akt (1:200; Santa Cruz), phospho-S6K (1:1000; Cell
Signaling), S6K1 (1:1000; Cell Signaling), phospho-S6 (1:1000;
Cell Signaling), S6 (1:1000; Cell Signaling), phospho-extracellular
signal-regulated kinase 1 and 2 (ERK1/2) (1:1000; Cell Signaling),
EGF receptor (Cell Signaling), IGF-I receptor (1:1000; Cell
Signaling), phospho-PTEN (Cell Signaling), PTEN (1:1000; Cell
Signaling) or b-actin (Cell Signaling). Membranes were washed,
then incubated for 1 hour with the appropriate secondary
antibodies (1:10000; Chemicon). The reaction was quantified
using the SuperSignal West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL, USA). Densitometric analysis was per-
formed by Kodak MJ project program. Data were expressed as
optical density.
siRNA transfection
TSC22/2ASM or TSC2-transformed cells were transfected with
small interfering RNA (siRNA) to reduce Akt isoforms. Custom-
made validated siRNAs for Akt1 isoforms were obtained from
Ambion (Austin, USA). The siRNA duplexes (50 nM) were
introduced with Lipofectamine 2000 (Invitrogen Corporation,
Carlsbad, USA) per manufacturer’s protocol. The cells were
assayed after 72 hours.
Statistical Analysis
All data are expressed as means values6SEM, and were
statistically analyzed using Student’s t-test; significance is indicated
for P values of *,0.005, **,0.01 and ***,0.001.
Results
Development of cells with stable expression of tuberin
from human TSC22/2ASM cells
TSC22/2 ASM cell proliferation required EGF in the culture
medium [15]. To study the correlation between the proliferative
role of EGF and tuberin in ASM cells, the full-length wild-type
human tuberin was successfully expressed in TSC22/2ASM cells
following retroviral transduction of the TSC2 gene (Fig. 1A and
1B). Expression and cellular distribution of tuberin was compa-
rable to that of normal human vascular smooth muscle cells
(VSMCs) and has been observed for up to 4 months. It was
localized primarily in the cell body and to a smaller extent in the
peripheral processes (Fig. 1B). The expression of EGF- and IGF-I-
receptors in TSC22/2ASM cells was not affected by TSC2
transfection (Fig. 1C); however, the responses to these factors were
significantly different in transfected and non-transfected cells.
Addition of EGF to the growth medium promotes proliferation of
human TSC22/2ASM cells [15], but, following TSC2 transfec-
tion, EGF inhibited proliferation (Fig. 1C). This action of EGF was
reported previously for VSMCs [15] and apparently results from
EGF-dependent early DNA synthesis, accompanied by minimal
cell division for 0 to 4 days, that leads to subsequent cell cycle
arrest [19]. TSC22/2ASM and TSC2-transfected cells grew at a
comparable rate in the medium lacking EGF. The addition of
IGF-I to the growth medium slightly improved the proliferation
rate of TSC2-transfected cells (Fig. 1C), as reported previously for
normal human smooth muscle cells [15].
Enhanced phosphorylations of Akt, S6K1 and S6 can be
considered a biochemical marker of TSC2 deficiency
[5,7,15,20,21]. The extent of Akt, S6K1 and S6 phosphorylation
was reduced in transformed cells compared to TSC22/2ASM
cells, while the expression of Akt and S6 proteins was unaltered
(Fig. 2A). PTEN phosphorylation was markedly lower in TSC2-
transfected cells compared to TSC22/2 ASM cells, and this was
similar to what was observed with Akt. As expected, the extent of
ERK phosphorylation was reduced by TSC2-transfection (Fig. 2A).
Thus, reduced Akt, PTEN, ERK, and S6 phosphorylation was
associated with TSC2 transfection as evidenced by the reduced
ratios of phosphorylated to specific protein level (Fig. 2B).
Effect of anti-EGFR antibody and rapamycin on TSC22/2
ASM cell growth and phenotype
From observations reported above, it appears that EGFR is
involved in proliferation of human TSC22/2 ASM cells.
Inhibitory effects of anti-EGFR antibody and rapamycin on
proliferation were observed by adding them to the culture medium
prior or after cell attachment to the dish. We chose the different
timing of application because cells may change the sensitivity to
drugs following adhesion. The addition of anti-EGFR antibody
(5 mg/ml) either at plating time or 3 hours after plating, led to an
early inhibition of TSC22/2ASM cell proliferation, followed by
almost complete cell death within 12 days (Fig. 3A). In contrast,
the addition of rapamycin (1 ng/ml) (at plating time), which
inhibits mTOR, slowed the proliferation rate of TSC22/2ASM
cells, while a delay of 3 hours eliminated the effects of rapamycin
on proliferation (Fig. 3B). The 1 ng/ml concentration of
rapamycin was used because it was able to reduce the TSC22/2
ASM cell growth rate to levels similar to controls in presence or
absence of EGF in the growth media as shown in Lesma et al.
[15]. We have also employed higher concentrations (up to 20 ng/
ml) of rapamycin, and only the highest concentrations of 10 and
20 ng/ml were able to slightly reduce the proliferation ability of
TSC22/2 ASM cells (Figure S1). All these concentrations,
similarly, to 1 ng/ml were capable of blocking the constitutive
phosphorylation of S6 (data not shown).
Exposure, at plating time, to rapamycin (1 ng/ml) and anti-
EGFR antibody greatly reduced S6 and ERK constitutive
phosphorylation at 48 hours (Fig. 4A). A delay of 3 hours in drug
addition however, revealed different responses of the two reagents.
Anti-EGFR antibody reduced both S6 and ERK phosphorylation
in 48 hours, while rapamycin reduced S6 phosphorylation but no
longer affected ERK activation (Fig. 4B). S6 phosphorylation
inTSC22/2 ASM cells was not affected by IGF-I (Figure 4A),
while ERK phosphorylation was slightly increased (Fig. 4A).
To correlate the effects of rapamycin and anti-EGFR antibody
on proliferation to changes in TSC22/2ASM cell phenotype,
gp100 expression, quantified with HMB45 antibody, was
examined after 48 hours and 5 days of drug exposure. TSC22/2
ASM cells are reactive with HMB45 antibody, a marker of TSC
and LAM cells [15,22]. HMB45 reactivity was quantified as strong
(++), intermediate (+) and negative (2). About 80% of untreated
TSC22/2ASM cells were strongly reactive with HMB45, 13%
slightly labelled, and 6% were negative (Fig. 5A). In contrast, after
a 48 hour incubation with anti-EGFR antibody added at plating
time, 25% of the cells were positive, 32% had an intermediate
labelling and 43% were negative (Fig. 5A). A 48 hour incubation
with rapamycin, added at plating time, reduced HMB45-reactive
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cells to 59%, while 19% were negative and 22% were slightly
labelled (Fig. 5A). After 5 days of exposure to rapamycin or anti-
EGFR antibody added at plating time, 49% and 71%, of TSC22/2
ASM cells, respectively, were not reactive with HMB45; anti-EGFR
antibody was still more effective (Fig. 5B). When anti-EGFR
antibody or rapamycin was added to the medium 3 hours after
plating the reversion of HMB45 reactivity was less marked at earlier
times (Fig. 5C), but after a 5 day incubation, both agents suppressed
reactivity (Fig. 5D). Following transformation with TSC2 gene, the
percentage of TSC22/2 ASM cells negative for the immunoblotting
of gp100 protein was greater than 80%, while actin expression was
unaffected (Fig. 5E and F). The observed differential sensitivity to the
effects of delayed addition of rapamycin on proliferation and gp100
protein expression in TSC22/2ASM cells suggests that these
molecular phenotypes may be regulated differently by TORC and
EGFR.
Role of PI3K pathway in TSC22/2 ASM cells
Binding of IGF-I to its receptor stimulates the intrinsic tyrosine
kinase activity of the receptor, leading to phosphorylation of
several substrates that activate downstream intracellular signaling
through the PI-3K or Grb2-SOS, ERK1/2 pathways [23].
Incubation of TSC22/2 ASM cells with IGF-I (50 ng/ml) for
2 hours, led to activation of PI3-K, and phosphorylation of Akt on
Ser473 (Fig. 6A). LY294002, a cell-permeable PI-3K inhibitor, at
20 mM, slightly inhibited IGF-I-mediated Akt activation without
Figure 1. Development of smooth muscle cells with stable human tuberin expression from human TSC22/2ASM cells. A: Expression
of tuberin was evaluated by Western blotting in TSC22/2ASM cells, TSC2-transfected cells (transf. cells), and AML. The slight expression in AML is due
to the presence of non-LOH TSC2 cells. B: Tuberin was undetectable by immunocytochemistry in TSC22/2ASM cells, but it was expressed in these
cells following TSC2 transfection. Aorta smooth muscle cells (VSMC) show immunolabeling of tuberin. C: Evaluation of EGF effects following TSC2-
gene transfection in TSC22/2ASM cells. Insert: EGFR and IGF-IR are expressed in TSC22/2ASM cells, TSC2-transfected cells, and AML. TSC22/2ASM cells
require, and TSC2-transfected cells (tTSC2 cells) do not require, EGF in the medium for cell proliferation. IGF-I promotes proliferation of TSC2-
transfected cells and normal smooth muscle cells. EGF has a negative effect on proliferation of transfected cells as it does on normal human smooth
muscle cells. Experiments were done three times each. Mean values6SEM. Significant differences (***P,0.001) versus control were evaluated by
student’s t-test.
doi:10.1371/journal.pone.0003558.g001
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affecting basal Akt phosphorylation (Fig. 6A and C). The lack of
effects of LY294002 and PD98059 on Akt phosphorylation was
confirmed by the densitometric analysis from 3 experiments
(Figure S2). Higher concentrations of LY294002 (100 mM) were
no more effective than 20 mM (data not shown). The extent of S6
and S6K1 phosphorylation was unaffected by treatment with IGF-
I, and LY294002 or PD98059, a specific ERK inhibitor (Fig. 6A
and C). The PI-3K inhibitor, wortmannin, a fungal metabolite,
which irreversibly binds mammalian PI-3K and inhibits phos-
phorylation of several other substrates (e.g. PLA2, PLD, myosin
chain kinase, plekstrin) [24,25] at 80 nM and 320 nM, in presence
or absence of IGF-I, did not affect Akt phosphorylation or
expression (data not shown).
In contrast to these findings, IGF-I-promoted Akt phosphory-
lation was fully LY294002-sensitive in TSC2-transformed cells
(Fig. 6B). LY294002 (20 mM) reduced both basal and IGF-I-
induced phosphorylation of Akt, S6 and S6K1 (Fig. 6B). Similar to
the findings with Akt, the basal and IGF-I-induced increase of S6
and S6K1 phosphorylation was also markedly reduced by
LY294002 addition to transfected cells (Fig. 6B).
To evaluate the role of ERK1/2, TSC22/2 ASM cells were
incubated with IGF-I and PD98059, which blocks MEK1 activity
and thus ERK phosphorylation and activation [26]. When 30 mM
or 90 mM PD98059 was added for 2 hours to the culture medium
in the presence or absence of IGF-I, no effect was observed on
phosphorylation of Akt, S6 and S6K1 (Fig. 6A, data not shown). In
TSC2-transfected cells, PD98059 did not affect Akt phosphoryla-
tion, but IGF-I-induced phosphorylation of S6 and S6K1 was
blocked. Expression of Akt and S6K1 was not altered by any
treatment (Fig. 6A, B). Following serum deprivation for 24 hours,
LY294002 or PD98059 failed to affect Akt, S6K and S6
phosphorylation in IGF-I-treated TSC22/2 ASM cells (Fig. 6C).
In TSC22/2 and TSC2-transfected ASM cells ERK phosphory-
lation was slightly increased by IGF-I exposure and inhibited by
PD98059 (Fig. 6A and B).
PTEN phosphatase acts as a negative regulator of the PI-3K
signaling pathway by dephosphorylating the second messengers
phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P3] and
phosphatidylinositol-3,4-bisphosphate [PtdIns(3,4)P2], thereby op-
posing PI-3K function [27]. It has been proposed that greater Akt
phosphorylation in TSC22/2 cells might be related to reduced
PTEN activity [28]. A 2 hour exposure to IGF-I (50 ng/ml)
enhanced PTEN phosphorylation in TSC22/2ASM cells in an
LY294002-insensitive manner (Fig. 6D). Following transformation
of cells with TSC2, LY294002 effectively blocked basal and IGF-I-
promoted phosphorylation of PTEN (Fig. 6D). These data suggest
that the extent of PTEN phosphorylation changes in parallel with
Akt activity. Higher levels of Akt phosphorylation were associated
with greater PTEN phosphorylation and vice versa.
To study further the role of AKT in TSC22/2 ASM cells,
endogenous Akt1 gene expression was inhibited by transient
transfection with Akt siRNA in the presence of EGF (Fig. 7). Akt1
siRNA reduced both Akt protein expression and phosphorylation,
indicating a greater preponderance of Akt1 in TSC22/2ASM
cells. Phosphorylation and expression of S6 and ERK were not
affected by Akt1 siRNA (Fig. 7A). The siRNA in TSC2 transfected
cells caused the drop of both Akt and phospho-Akt levels that,
differently that in TSC2/2 ASM cells, is accompanied by the
reduction in the extent of S6 phosphorylation (Fig. 7B). Such effect
was also observed in normal vascular smooth muscle cells VSMCs
(data not shown).
Discussion
We had previously reported the isolation of TSC22/2ASM cells
from an angiomyolipoma of a TSC patient [15]. These cells have
been grown for the past 4 years, and the original morphological,
genetic and biochemical characteristics, such as reactivity to anti-
a-actin and HMB45 antibodies, and EGF-dependent growth,
were fully maintained.
Deregulation of the pathways that control cell proliferation and
survival, such as those regulated by Ras/MAPK and PI3K, is a
major characteristic of abnormal tumor growth and following
mutations of tumor-suppressor genes leads to the formation of
benign, rather than malignant, tumors. The rate of proliferation of
Figure 3. Effect of anti-EGFR antibody and rapamycin (rapa) on
TSC22/2ASM cell growth. A: 72 hour incubation: anti-EGFR antibody
incubation (5 mg/ml) at plating time and 3 hours after plating inhibited
proliferation and caused a marked TSC22/2ASM cell death. B:
Incubation at plating time with rapamycin (1 ng/ml) slowed signifi-
cantly TSC22/2ASM cell growth, while its addition at 3 hours after
plating failed to affect proliferation. Mean values6SEM. Significant
differences (*P,0.05, ***P,0.001) versus control were evaluated by
student’s t-test.
doi:10.1371/journal.pone.0003558.g003
Figure 2. Biochemical rearrangements promoted by TSC2 transfection. A: Constitutive phosphorylation of Akt, PTEN, S6K1, and S6 was
markedly decreased by TSC transfection; interestingly also the extent of ERK phosphorylation was reduced. B: Also the phosphorylated form to total
protein ratio shows a marked reduction of the extent of phosphorylation caused by TSC2-gene transfection. The blots are representative of three
separate experiments.
doi:10.1371/journal.pone.0003558.g002
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TSC22/2 ASM cells is sensitive to the addition of EGF to the
growth medium, while secretion of IGF-I is involved in survival
[15,16]. Here, we report that the viral-induced expression of
tuberin in TSC22/2 ASM cells greatly reduced the growth rate,
EGF ceased to be a required growth factor, and instead, it
inhibited proliferation. These results support the original hypoth-
esis that the EGF requirement for TSC22/2ASM cell prolifera-
tion is dependent upon the lack of tuberin. Similar to what it is
observed in normal smooth muscle cells, IGF-I slightly enhanced
the proliferation rate of transfected cells [15,29]. TSC2-transfec-
tion reversed the typical features of human TSC22/2ASM cells,
i.e. the abnormal EGF-dependent proliferation, constitutive S6
phosphorylation, and reactivity with HMB45 without affecting the
smooth muscle phenotype.
Further extending the previous study [15], we evaluated the
action of anti-EGFR antibody and rapamycin in regulating
TSC22/2 ASM cell growth. EGFR is an important target of
anticancer therapy. The EGFR signalling pathways regulate cell
differentiation, proliferation, migration, angiogenesis and apoptosis,
all of which become deregulated in cancer cells [30]. One current
strategy to block cancer growth involves the use of antibodies
against the extracellular domain of EGFR, which compete with
ligand for receptor binding, thereby preventing kinase activation
[30]. As an example, the antibody used in this study, monoclonal
antibody C225, has a high affinity for EGFR and has been shown to
be efficacious in several types of cancer, particularly colorectal and
head and neck cancers [30]. Rapamycin specifically inhibits
mTOR, while anti-EGFR blocks a complex pathway that involves
ERK, RSK1 and tuberin [31]. Rapamycin has been shown to
induce apoptosis, decrease proliferation, and reduce tumor size in
the Eker rat model and in TSC2+/2 mice [32,33]. Since mTOR is
directly activated upon loss of hamartin or tuberin, rapamycin has
been identified as a potential therapeutic agent for TSC and LAM.
It has been recently reported that angiomyolipomas of TSC patients
regressed partially during rapamycin treatment, but the volume
increased again after the therapy was stopped [34]. Our data
indicate that anti-EGFR antibody has a greater ability than
rapamycin to inhibit proliferation of TSC22/2 ASM cells,
counteract the phosphorylation of S6 and ERK, and reduce
HMB45 reactivity. Furthermore, the anti-EGFR antibody-depen-
dent reduction of the proliferation rate led to the progressive death
of human TSC22/2ASM cell when added to the medium either at
plating time or 3 hours after plating. In contrast, rapamycin
reduced significantly cell proliferation only when added prior cell
attachment. The delayed application of rapamycin did not affect
TSC22/2 ASM cell proliferation although S6 constitutive phos-
Figure 4. Effect of rapamycin (rapa) (1 ng/ml) and anti-EGFR (5 mg/ml) and IGF-I (50 ng/ml) on phosphorylation of S6 and ERK. The
blots are representative of three experiments. A: Incubation with rapamycin at plating time for 24 or 48 hours inhibited S6 phosphorylation even in
the presence of IGF-I. Also anti-EGFR antibody affected the extent of S6 phosphorylation at 48 hours. ERK phosphorylation is reduced by both agents
after 48 hours. B: When the drugs are added 3 hours after cell plating, rapamycin reduces S6 phosphorylation in 24 and 48 hours incubation but
failed to affect ERK phosphorylation. Anti-EGFR antibody inhibited both S6 and ERK phosphorylation within 48 hours. IGF-I alone did not affect the
extent of S6 and ERK phosphorylation.
doi:10.1371/journal.pone.0003558.g004
Pharmacology of TSC22/2Cells
PLoS ONE | www.plosone.org 7 October 2008 | Volume 3 | Issue 10 | e3558
Figure 5. Effect of rapamycin (1 ng/ml) and anti-EGFR antibody (5 mg/ml) on reactivity with monoclonal HMB45 in human TSC22/2
ASM cells. Positive cells are indicated as ++, slightly positive as + and negative as 2. A: Incubation at cell plating time with anti-EGFR for 48 hours
decreases markedly the number of cells reacting to HMB45 while the number of negative cells is strongly increased. Rapamycin is markedly less than
anti-EGFR antibody. B: Incubation for 5 days with either rapamycin or anti-EGFR antibody, applied at cell plating time, caused a significant reduction
of HMB45 reactivity in both cases. C: 48 hours exposure to rapamycin or anti-EGFR antibody, both applied 3 hours after plating, caused only a slight
reduction of HMB45 reactivity of TSC22/2ASM cells. D: Exposure to rapamycin or anti-EGFR antibody applied 3 hours after cell plating for 5 days
caused a drastic reduction in HMB45 reactivity of TSC22/2ASM cells. E: Transfection of TSC22/2 ASM cells with TSC2 gene significantly reduced
HMB45 reactivity. F: a-actin was present in both TSC22/2ASM and TSC2-transfected cells. Mean values6SEM. Significant differences (*P,0.05,
**P,0.01, ***P,0.001) versus control were evaluated by student’s t-test.
doi:10.1371/journal.pone.0003558.g005
Pharmacology of TSC22/2Cells
PLoS ONE | www.plosone.org 8 October 2008 | Volume 3 | Issue 10 | e3558
phorylation is inhibited. This may be explained by the activity of
MAPK in these cells. Anti-EGFR antibody and rapamycin,
however, were clearly less efficient than TSC2-transfection.
Consistent with the concept that S6K1 activation is PI3K
independent in tuberin-deficient cells, Akt1 siRNA did not
interfere with S6 phosphorylation, while PTEN phosphorylation
in TSC22/2 and TSC2-transfected cells followed the activation
pattern of Akt. Exposure to IGF-I enhanced Akt phosphorylation
of both TSC22/2 ASM cells and those virally transfected with
TSC2 gene; however, PI3K inhibitors, such as LY294002 and
wortmannin, were able to affect this process only in TSC2-
transfected cells. Thus, it appears that viral-induced expression of
Figure 6. Phosphorylation of Akt, SK1 and S6 in TSC22/2ASM cells and following TSC2 transfection. A: Incubation of TSC22/2ASM cells
for 2 hours with IGF-I (50 ng/ml) induced Akt phosphorylation but did not affect S6K1 and S6 phosphorylation. Incubation with PI3K inhibitor,
LY294002 (LY; 20 mM), or ERK inhibitor, PD98059 (PD; 30 mM), did not influence the activation of Akt, S6K1 and S6. Expression of Akt, and S6K1 was
not altered by any treatment. B: Following TSC2 transfection, LY290042 antagonized IGF-I-mediated and basal phosphorylation of Akt, S6K1, and S6.
Expression of Akt, and S6K1 proteins were unaltered. C: Following 24 hours of starvation, phosphorylation of S6K1 and S6, and expression of Akt and
S6K1 proteins were unaltered by 2 hour incubation with IGF-I in presence or absence of LY290042 or PD98059. Increased phosphorylation of Akt
caused by IGF-I, was unaffected by incubation with LY290042 or PD98059. D: PTEN regulation in TSC22/2ASM cells. In TSC22/2ASM cells,
phosphorylation of PTEN was increased by incubation for 2 hours with IGF-I (50 ng/ml), and this was not inhibited by LY290042 (20 mM) as observed
above for Akt phosphorylation. Following TSC2 transfection, LY290042 effectively inhibited basal and IGF-I promoted phosphorylation of PTEN as
described above for Akt.
doi:10.1371/journal.pone.0003558.g006
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tuberin in TSC22/2 ASM cells modifies cellular function and
sensitivity to drugs.
Serum-stimulated phosphorylation of tuberin was observed in
embryonic fibroblasts from Akt1/Akt2 double knockout mice,
consistent with the hypothesis that another kinase, such as RSK1,
phosphorylates tuberin in response to stimuli that activate the
Ras/MAPK pathway [35]. Tuberin is a phosphorylation target of
Ras-ERK signalling and phosphorylation results in the suppression
of its biochemical and biological tumor-suppressive functions [13].
Viral-driven tuberin expression in TSC22/2ASM cells decreased
phosphorylation of p42/44 MAPK. This effect was also observed
with anti-EGFR antibody, whereas rapamycin had a similar effect
only when added at plating time. The data are consistent with a
regulatory mechanism by which the Ras/MAPK and PI3K
pathways converge on tuberin to inhibit its function [12]. In
human TSC22/2 ASM cells, the lack of tuberin seems to shift the
regulation of cell proliferation to the Ras/MAPK pathway while
PI3K cascade appears to activate an independent and different cell
signalling pathway (Figure 8). This may explain why IGF-I which
has a proliferative action in normal smooth muscle cells, fails to
promote proliferation in TSC22/2 ASM cells, and activates
survival pathways [16]. From our results it may be also inferred a
possible modulation of mTOR by the EGF pathway. We may
speculate that, in TSC22/2 ASM cells, Akt is highly phosphor-
ylated because its major substrate, tuberin, is absent while the
phosphorilative events are particularly active, expecially mTOR-
rictor. In this situation Akt is insensitive to PI3K inhibitors but
following TSC2 transfection the sensitivity is restored.
In conclusion, re-expression of tuberin caused a more efficient
reversion of phenotypic, proliferative and biochemical character-
Figure 7. Transient transfection with siRNA for Akt1 in TSC22/
2ASM and TSC2-transfected cells. A: In TSC22/2ASM cells siRNA for
Akt1 drastically inhibited Akt expression and phosphorylation, but it did
not affect PTEN, S6 and ERK expression and activation. B: In TSC2-
transfected cells siRNA for Akt1 inhibited the level and the phosphor-
ylation of Akt and S6 phosphorylation.
doi:10.1371/journal.pone.0003558.g007
Figure 8. ERK- and PI3K-Akt-dependent cascades regulating mTOR signalling. A: In wild type cells, activation of either pathways result in
the phosphorylation of both RSK1 and Akt that, in turn, are capable of phosphorylating tuberin directly. B: In TSC22/2 ASM cells, the loss of tuberin
may lead to modification of ERK-RSK1 function with direct/indirect regulation of mTOR and p706K. ERK-RSK1 pathway appears to have a more
relevant role while the PI3K cascade, may not be properly regulated. This might explain the EGF requirement for proliferation of TSC22/2 ASM cells.
doi:10.1371/journal.pone.0003558.g008
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istics of TSC22/2ASM cells compared to the pharmacological
approach. EGF-dependent TSC22/2 ASM proliferation is related
to the lack of tuberin. The anti-EGFR antibody was more efficient
than rapamycin in reducing reactivity to HMB45, the proliferation
rate, and in controlling ERK activation in human TSC22/2ASM
cells. Both rapamycin and anti-EGFR were equally affected in
inhibiting S6 activation, while ERK phosphorylation was more
sensitive to anti-EGFR. In TSC22/2 ASM cells, the EGF
pathway, involving ERK, may play a more relevant role than a
PI3K cascade in cell growth.
Supporting Information
Figure S1 Effect of rapamycin (rapa) on TSC22/2ASM cell
growth. Rapamycin addition at the concentrations of 5 ng/ml
3 hours after plating did not have any significant effect on cell
growth while 10, and 20 ng/ml slowed TSC22/2ASM prolifer-
ation only after 7 days of incubation. Mean values6SEM.
Significant differences (*P,0.05) versus control were evaluated
by student’s t-test
Found at: doi:10.1371/journal.pone.0003558.s001 (5.76 MB TIF)
Figure S2 Densitometric analysis of phosphorylation of Akt in
TSC22/2ASM cells in complete medium or following 24 hours
starvation. Incubation of TSC22/2ASM cells and following
TSC2-transfection for 2 hours with IGF-I (50 ng/ml) induced
Akt phosphorylation. Incubation with PI3K inhibitor, LY294002
(LY; 20 mM), or ERK inhibitor, PD98059 (PD; 30 mM), did not
influence the activation of Akt. Expression of Akt was not altered
by any treatment. Mean values6SEM. Significant differences
(***P,0.001) versus control were evaluated by student’s t-test.
Found at: doi:10.1371/journal.pone.0003558.s002 (7.38 MB TIF)
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